AddLife AB (ALIF.B) AI Stock Analysis

• Market Cap: kr18.95B
• Dividend Yield: 0.46%
• Average Volume (3M): 97.37K
• Price to Earnings (P/E): 47.2
• Beta (1Y): 0.52
• Revenue Growth: 5.14%
• EPS Growth: 236.75%
• Country: SE
• Employees: 2,251
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.29
• Shares Outstanding: 117,877,460
• 10 Day Avg. Volume: 108,367
• 30 Day Avg. Volume: 97,373
• PEG Ratio: 2.03
• Price to Book (P/B): 3.15
• Price to Sales (P/S): 1.63
• P/FCF Ratio: 20.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: kr166.00 ▲(7.03% Upside)

AddLife AB's strong financial performance, characterized by revenue growth and operational efficiency, is a key strength. However, the high P/E ratio and low dividend yield suggest valuation concerns. Technical indicators show neutral market sentiment, contributing to a moderate overall stock score.

Positive Factors

Diversified distribution model and partnerships

AddLife’s core distribution model across medical devices, lab equipment and consumables, combined with partnerships and value-added services (training, maintenance), creates recurring revenue streams and deep customer relationships that support sustained sales and retention across healthcare and research markets.

Strong recent revenue growth with stable margins

An 81.4% TTM revenue uplift alongside a steady ~37.8% gross margin indicates the company is scaling sales while retaining product-level profitability. This combination supports sustainable operating leverage, enabling reinvestment into sales, service capabilities, and selective product expansion over the medium term.

High cash conversion and steady operating cash flow

Consistently improving operating cash flow and a FCF-to-net-income ratio near 96% reflect strong conversion of earnings into cash. This durable cash-generation ability supports working-capital needs, maintenance capex and bolt-on M&A without immediate reliance on equity financing.

Negative Factors

Low net profit margin

A net margin of ~3.2% leaves limited buffer against cost inflation, pricing pressure or integration costs from acquisitions. Over the medium term this constrains the company’s ability to expand retained earnings, fund organic growth, and absorb shocks without pursuing margin improvement or structural cost actions.

Stagnant free cash flow growth

Although conversion is strong, stagnating free cash flow growth limits the accumulation of cash reserves needed for larger strategic moves, sustained capex increases, or dividend expansion. Over 2–6 months this could constrain flexibility for M&A or buffering cyclical downturns.

Moderate equity ratio and near-1 leverage

A debt-to-equity near 1.0 and only a moderate equity ratio imply the company carries meaningful leverage. In a period of rising rates or weaker cashflow, this reduces financial flexibility, increases refinancing risk, and may limit the pace of opportunistic investments without deleveraging.

AddLife AB Business Overview & Revenue Model

Company Description

AddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments segments. This segment also offers support, maintenance, advice, and training services. The Medtech segment provides medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, fall prevention, welfare technology, ear, and nose and throat segments, as well as bathroom-related assistive devices and assistive devices for children with disabilities. It operates in Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.

How the Company Makes Money

AddLife AB generates revenue through multiple streams, primarily focusing on the sale of medical and laboratory products. The company's revenue model is driven by its distribution business, which involves sourcing products from various manufacturers and selling them to healthcare facilities, laboratories, and research institutions. Key revenue streams include direct sales of medical devices, laboratory equipment, and consumables, as well as service agreements and maintenance contracts. Additionally, AddLife benefits from strategic partnerships with leading manufacturers, which enhance its product offerings and market reach. The company also invests in value-added services such as training and support, which contribute to customer loyalty and recurring revenue. Overall, AddLife's diverse product portfolio and strong industry relationships are critical factors that bolster its financial performance.

AddLife AB Financial Statement Overview

Summary

AddLife AB shows strong revenue growth and operational efficiency with stable gross margins. The balance sheet reflects prudent debt management, but there is room for improvement in profitability and cash flow growth.

Income Statement

AddLife AB has demonstrated consistent revenue growth, with a notable increase of 81.4% in the TTM period. The gross profit margin remains stable around 37.8%, indicating efficient cost management. However, the net profit margin is relatively low at 3.2%, suggesting room for improvement in profitability. The EBIT and EBITDA margins have shown slight improvements, reflecting operational efficiency gains.

Balance Sheet

The company's debt-to-equity ratio has improved slightly to 0.96, indicating a balanced approach to leveraging. Return on equity has increased to 6.5% in the TTM period, showing better utilization of equity. However, the equity ratio remains moderate, suggesting a balanced asset structure but with potential risks if debt levels increase.

Cash Flow

Operating cash flow has shown a steady increase, supporting the company's operations effectively. The free cash flow to net income ratio is strong at 95.7%, indicating good cash generation relative to net income. However, free cash flow growth has stagnated, highlighting potential challenges in expanding cash reserves.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.53B	10.29B	9.69B	9.08B	7.99B	5.27B
Gross Profit	3.98B	3.86B	3.60B	3.43B	2.86B	1.82B
EBITDA	1.03B	1.52B	1.53B	1.45B	1.46B	951.00M
Net Income	394.00M	252.00M	190.00M	480.00M	719.00M	517.80M
Balance Sheet
Total Assets	12.66B	13.05B	12.74B	13.06B	10.60B	4.15B
Cash, Cash Equivalents and Short-Term Investments	286.00M	331.00M	272.00M	376.00M	345.30M	216.00M
Total Debt	5.02B	5.07B	5.29B	5.59B	4.10B	805.80M
Total Liabilities	7.35B	7.75B	7.79B	8.09B	6.30B	2.26B
Stockholders Equity	5.30B	5.31B	4.96B	4.97B	4.29B	1.88B
Cash Flow
Free Cash Flow	1.11B	798.00M	465.00M	627.00M	866.30M	857.90M
Operating Cash Flow	1.17B	1.09B	773.00M	909.00M	1.01B	950.10M
Investing Cash Flow	-511.00M	-386.00M	-317.00M	-1.09B	-2.98B	-428.70M
Financing Cash Flow	-591.00M	-682.00M	-554.00M	134.00M	2.07B	-372.50M

AddLife AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 155.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALIF.B, the sentiment is Negative. The current price of 155.1 is below the 20-day moving average (MA) of 163.22, below the 50-day MA of 178.13, and below the 200-day MA of 177.11, indicating a bearish trend. The MACD of -7.26 indicates Positive momentum. The RSI at 28.74 is Positive, neither overbought nor oversold. The STOCH value of 33.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ALIF.B.

AddLife AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VITR	71 Outperform	kr17.59B	40.96	3.34%	0.80%	-1.29%	―
BONEX	66 Neutral	kr11.96B	77.68	19.59%	―	37.41%	67.03%
ALIF.B	64 Neutral	kr18.95B	47.23	7.24%	0.46%	5.14%	236.75%
VIMIAN	64 Neutral	kr17.08B	47.56	4.63%	―	17.13%	―
EKTA.B	55 Neutral	kr23.04B	78.29	3.08%	4.25%	-0.90%	-70.95%
PAX	52 Neutral	kr1.32B	203.46	1.41%	―	21.71%	-80.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

AddLife AB Corporate Events

AddLife AB Acquires Opitek International to Boost Orthopedic Segment

AddLife AB has acquired Opitek International ApS, a Danish MedTech company specializing in patient positioning solutions, to enhance its Mediplast division. This strategic acquisition is expected to bolster AddLife’s presence in the orthopedic segment by leveraging Opitek’s innovative product portfolio and established customer relationships. The move aligns with AddLife’s growth strategy, aiming to expand its own brands and accelerate market reach, potentially leading to long-term profitable growth.

The most recent analyst rating on ($SE:ALIF.B) stock is a Hold with a SEK200.00 price target. To see the full list of analyst forecasts on AddLife AB stock, see the SE:ALIF.B Stock Forecast page.

AddLife AB Expands with Acquisition of Pharmacold A/S

AddLife AB has acquired Pharmacold A/S, a Danish specialist in refrigeration technology for the pharmaceutical and healthcare sectors. This acquisition, which aligns with AddLife’s strategic goals, will enhance its service offerings and market position in Denmark. Pharmacold will operate as a subsidiary under Holm & Halby, a company within AddLife’s Labtech business area. The acquisition is expected to have a marginally positive impact on AddLife’s earnings per share for the current financial year.

The most recent analyst rating on ($SE:ALIF.B) stock is a Hold with a SEK200.00 price target. To see the full list of analyst forecasts on AddLife AB stock, see the SE:ALIF.B Stock Forecast page.

AddLife AB Reports Strong Q3 2025 Performance and Strategic Acquisition

AddLife AB reported strong financial performance for the third quarter of 2025, with a 4% increase in net sales and a significant 228% rise in profit after tax. The company also completed the acquisition of Edge Medical Ltd., which is expected to boost annual sales by SEK 90m, further strengthening its market position.

The most recent analyst rating on ($SE:ALIF.B) stock is a Hold with a SEK195.00 price target. To see the full list of analyst forecasts on AddLife AB stock, see the SE:ALIF.B Stock Forecast page.